ALISO VIEJO, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, announces that the SCOUT® RADAR breast localization system has been honored with the 2017 Gold Annual Medical Design Excellence Award (MDEA) in the “ER and OR Tools, Equipment and Supplies” category. The MDEA recognizes technological achievements of medical device manufacturers in medical product design and engineering.
SCOUT® is the market leader in non-radioactive, wire-free breast localization systems. With SCOUT, the radiologist places a tiny reflector at the tumor site. This can be done up to 30 days prior to surgery versus on the same day of surgery, which is required with traditional wire localization. Instead of two procedures on the day of surgery, the patient now undergoes one, which can help make the experience significantly less stressful.
This novel technology, which has been rapidly adopted at over 130 leading medical facilities across the United States, offers several benefits over other localization methods including operating room compatibility, ± 1mm detection accuracy and no significant MRI compatibility issues or artifact limitations.
“We are honored to receive gold in the 2017 Annual Medical Design Excellence Awards and we’re grateful to be recognized among so many leading innovators,” said Jill Anderson, President and CEO of Cianna Medical. “This recognition, which follows rapid adoption of SCOUT nationwide and comes amid reports of strong satisfaction from the professional and patient communities, is further validation that we are fulfilling an unmet medical need.”
The MDEA is the premier awards program for the medtech industry. Since its inception in 1998, the mission of the MDEA has been to recognize significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. Products are judged based on design and engineering innovation, function and user-related innovation, patient benefits, business benefits and overall benefit to the healthcare system. Awards were granted across nine categories and included gold, silver and bronze winners in each. The 2017 winners were announced at a ceremony on June 13, 2017 at the Jacob K. Javits Convention Center in New York.
For more information, call 866.920.9444 or visit www.ciannamedical.com.
About SCOUT®
The FDA-cleared SCOUT system features a proprietary, highly sophisticated reflector that is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This higher level of localization precision allows better surgical planning that may improve cosmetic results, as less tissue may need to be removed. SCOUT has an exceptional detection range of 1mm – 50mm, documented migration of <1% across multiple studies, and is OR compatible.i
About Radar Technology
The SCOUT system uses highly sophisticated radar technology. Radar is used when unprecedented precision is required. Applications using radar include ground penetrating radar, automobile safety systems, flight control systems and antimissile and air-defense systems.
About Cianna Medical, Inc.
Cianna Medical is the world leader in wire-free breast localization and has been focused on breast conservation for over 10 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical’s world-class research, development and commercialization teams developed the world’s first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT and SAVI® Brachy technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance.
______________________________________
i Cox CE, Russell S, Prowler V, et al. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol. 2016;23(10):3168-74.